Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 774 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06985485RecruitingPhase 2
Immunotherapy for older or frail B-ALL patients
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
Suzhou, JiangsuAges 15 years+ - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
Little Rock, ArkansasAges 12–55 - NCT07062055RecruitingPhase 2
A study of combination therapy for advanced liver cancer with spread
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Jinan, ShandongAges 18–70 - NCT07069842Recruiting
Gastric cancer immunotherapy prediction model
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Changzhi, ShanxiAges 18–75 - NCT07080437Recruiting
Immunotherapy and chemoradiation for elderly esophageal cancer patients
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
Chongqing, Chongqing MunicipalityAges 70 years+ - NCT07091305RecruitingPhase 2
Study of a new drug with chemotherapy for limited-stage small cell lung cancer
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
ShanghaiAges 18–75 - NCT07092696RecruitingPhase 2
Immunotherapy and chemoradiation for cervical cancer
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
TianjinAges 18–75 - NCT07113275RecruitingPhase 3
Short versus long radiation schedule for advanced rectal cancer
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Wuhan, HubeiAges 18–75 - NCT07121374RecruitingPhase 1/Phase 2
Chemotherapy and immunotherapy before possible surgery for mesothelioma
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
Edegem, AntwerpAges 18 years+ - NCT07131007Recruiting
Early warning system for immunotherapy side effects
This study is for people with cancer who are already receiving immunotherapy (checkpoint inhibitors). It aims to build an early warning system to help detect and manage possible organ damage or other side effects from the treatment, using advanced testing to keep you safer.
Shijiazhuang, HebeiAges 18–80 - NCT07138547RecruitingPhase 1/Phase 2
Eliglustat plus CD30 immunotherapy for CD30+ lymphoma
This trial tests a combination of two medicines (eliglustat and a CD30-targeted immunotherapy) for people with a type of lymphoma that has a specific marker called CD30. It aims to see if this combination can help when standard treatments have already been used.
Beijing, Beijing MunicipalityAges 18–75 - NCT07166003Recruiting
Immunotherapy before surgery for lung cancer
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
BeijingAges 18–79 - NCT07198165RecruitingPhase 2
Short radiation followed by chemo plus bevacizumab with or without immunotherapy for rectal cancer
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
ShanghaiAges 18–75 - NCT07204132Recruiting
Freezing and Immunotherapy for Bladder Cancer
This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07224971RecruitingPhase 2
Timing of immunotherapy for advanced cancer
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07239466RecruitingPhase 2
Ketone supplement with radiation and chemo for rectal cancer
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
Wuhan, HubeiAges 18–75 - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT07260370Recruiting
Studying blood markers in cancer patients on immunotherapy
This study looks at tiny particles (microRNA) and cancer cells in the blood of people with cancer who are getting immunotherapy. It aims to find patterns that might help doctors better understand how the treatment is working.
Taoyuan CityAges 20 years+ - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT07305428Recruiting
Making large liver tumors removable with immunotherapy and focused radiation
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
Hong KongAges 18–80 - NCT07312604Recruiting
Testing an injection therapy for stubborn ringworm infections
This study tests a new type of injection treatment for stubborn ringworm (tinea) infections that haven't improved with standard pills or creams. It aims to see if this immunotherapy works better for hard-to-treat cases, especially when the fungus might be resistant to usual medicines.
Al Mansurah, Dakahlia GovernorateAges 10–60 - NCT07384897Recruiting
Immune cells in lung cancer and chronic lung disease
This study looks at how immune cells work in lung cancer and chronic lung diseases. It aims to find better ways to treat these conditions by studying immune cells from blood, bone marrow, or lung samples.
BrusselsAges Up to 80 years - NCT07396259Recruiting
PD-L1 test in blood to predict immunotherapy success
This trial is monitoring changes in a cancer protein called PD-L1 in head and neck cancer patients before and during immunotherapy treatment. It aims to better understand how well immunotherapy will work by using regular blood tests.
Taoyuan, CityAges 18 years+ - NCT06748404RecruitingPhase 2
TriCalm Hydrogel for Itching from Immunotherapy
This trial tests a gel called TriCalm Hydrogel to see if it helps reduce itching caused by immunotherapy cancer treatment. If you have itching from your immunotherapy, this study might offer relief.
La Jolla, CaliforniaAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 774 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.